{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:23:07Z","timestamp":1756902187574,"version":"3.44.0"},"reference-count":22,"publisher":"The Pediatric Pharmacy Association","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"abstract":"<jats:p>\n          <jats:bold>OBJECTIVES<\/jats:bold> Vancomycin weight-based dosing regimens often fail to achieve therapeutic trough serum concentration in children \u226412 years of age and rigorous studies evaluating efficacy and safety of body surface area (BSA)\u2013based dosing regimens have not been performed. We compared vancomycin trough serum concentrations in pediatric patients receiving a weight- or BSA-based dosing regimen.<\/jats:p>\n        <jats:p>\n          <jats:bold>METHODS<\/jats:bold> This was a single-center, retrospective study evaluating pediatric patients, ages 1 to 12 years, who received vancomycin from September 2012 to October 2015. Patients received a minimum of 3 consecutive doses at the same scheduled interval within a dosing regimen prior to a measured vancomycin serum trough concentration. The primary outcome was percentage of initial vancomycin trough concentrations \u226510 mg\/L. The secondary outcomes were percentage of supratherapeutic, therapeutic, and subtherapeutic vancomycin serum concentration for all patients, including a subset of overweight and obese patients, and number of nephrotoxic occurrences.<\/jats:p>\n        <jats:p>\n          <jats:bold>RESULTS<\/jats:bold> BSA-based dosing regimens resulted in 50% of the initial vancomycin trough concentrations \u2265 10 mg\/L compared with 17% for the weight-based dosing regimens (p &lt; 0.0001). No statistically significant differences were noted between the 2 dosing regimens for supratherapeutic, therapeutic, or subtherapeutic trough concentrations for all patients, and for the subset of overweight and obese patients. Nephrotoxic occurrences were noted in 7% of the weight-based dosing regimens compared with none in the BSA-based dosing regimens.<\/jats:p>\n        <jats:p>\n          <jats:bold>CONCLUSIONS<\/jats:bold> A BSA-based vancomycin dosing regimen resulted in significantly more initial vancomycin trough concentrations \u226510 mg\/L and trended towards higher initial vancomycin trough concentrations without observable nephrotoxicity.<\/jats:p>","DOI":"10.5863\/1551-6776-24.4.296","type":"journal-article","created":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T20:39:48Z","timestamp":1563223188000},"page":"296-303","source":"Crossref","is-referenced-by-count":3,"title":["Use of Body Surface Area for Dosing of Vancomycin"],"prefix":"10.5863","volume":"24","author":[{"given":"Elizabeth L.","family":"Sawrey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary W.","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kacy A.","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandy S.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany B.","family":"Logston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory B.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"issue":"5","key":"i1551-6776-24-4-296-b1","series-title":"Pediatr Infect Dis J","first-page":"462","article-title":"Use of vancomycin in pediatrics","volume":"29","year":"2010","unstructured":"Dehority\n              W.\n            \n          \n          Use of vancomycin in pediatrics. Pediatr Infect Dis J. 2010;29(5):462\u2013464."},{"issue":"3","key":"i1551-6776-24-4-296-b2","series-title":"Clin Infect Dis","first-page":"1","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","year":"2011","unstructured":"Liu\n              C\n            , BayerA, CosgroveSE, \n          et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):1\u201338."},{"issue":"3","key":"i1551-6776-24-4-296-b3","series-title":"Pediatr Infec Dis J","first-page":"263","article-title":"Healthcare-associated Staphylococcus aureus bacteremia in children: evidence for reverse vancomycin creep and impact of vancomycin trough values on outcome","volume":"35","year":"2016","unstructured":"McNeil\n              JC\n            , KokEY, ForbesAR, \n          et al. Healthcare-associated Staphylococcus aureus bacteremia in children: evidence for reverse vancomycin creep and impact of vancomycin trough values on outcome. Pediatr Infec Dis J. 2016;35(3):263\u2013268."},{"issue":"6","key":"i1551-6776-24-4-296-b4","series-title":"Pediatric Infec Dis J","first-page":"572","article-title":"The influence of the route of antibiotic administration, methicillin susceptibility, vancomycin duration and serum trough concentration on outcomes of pediatric Staphylococcus aureus bacteremic osteoarticular infection","volume":"36","year":"2017","unstructured":"McNeil\n              JC\n            , KaplanSL, VallegoJG.\n          The influence of the route of antibiotic administration, methicillin susceptibility, vancomycin duration and serum trough concentration on outcomes of pediatric Staphylococcus aureus bacteremic osteoarticular infection. Pediatric Infec Dis J. 2017;36(6):572\u2013577."},{"issue":"12","key":"i1551-6776-24-4-296-b5","series-title":"Pharmacotherapy","first-page":"1264","article-title":"The effect of age and weight on vancomycin serum trough concentrations in pediatric patients","volume":"33","year":"2013","unstructured":"Madigan\n              T\n            , SieveRM, GranerKK, \n          et al. The effect of age and weight on vancomycin serum trough concentrations in pediatric patients. Pharmacotherapy. 2013;33(12):1264\u20131272."},{"issue":"7","key":"i1551-6776-24-4-296-b6","series-title":"Pediatr Infect Dis J","first-page":"731","article-title":"Clinical evaulation of vancomycin dosage in pediatric oncology patients","volume":"33","year":"2014","unstructured":"Sanders\n              SJ\n            , BijleveldYA, SinkelerF, \n          et al. Clinical evaulation of vancomycin dosage in pediatric oncology patients. Pediatr Infect Dis J. 2014;33(7):731\u2013733."},{"issue":"12","key":"i1551-6776-24-4-296-b7","series-title":"Pharmacothearpy","first-page":"1273","article-title":"Vancomycin trough concentrations in overweight or obese pediatric patients","volume":"33","year":"2013","unstructured":"Heble\n              DE\n            , McPhersonC, NelsonMP, \n          et al. Vancomycin trough concentrations in overweight or obese pediatric patients. Pharmacothearpy. 2013;33(12):1273\u20131277."},{"issue":"4","key":"i1551-6776-24-4-296-b8","series-title":"Pediatr Infect Dis J","first-page":"e155","article-title":"Improved vancomycin dosing in children using area under the curve exposure","volume":"32","year":"2013","unstructured":"Le\n              J\n            , BradleyJS, MurrayW, \n          et al. Improved vancomycin dosing in children using area under the curve exposure. Pediatr Infect Dis J. 2013;32(4):e155\u2013e163."},{"issue":"5","key":"i1551-6776-24-4-296-b9","series-title":"Ann Pharmacother","first-page":"582","article-title":"Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients","volume":"45","year":"2011","unstructured":"Eiland\n              LS\n            , EnglishTM, EilandEHIII.\n          Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients. Ann Pharmacother. 2011;45(5):582\u2013589."},{"issue":"3","key":"i1551-6776-24-4-296-b10","series-title":"J Ped Infect Dis","first-page":"259","article-title":"Vancomycin dosing practices, trough concentrations, and predicted area under the curve in children with suspected invasive staphylococcal infections","volume":"2","year":"2013","unstructured":"Chhim\n              RF\n            , ArnoldSR, LeeKR.\n          Vancomycin dosing practices, trough concentrations, and predicted area under the curve in children with suspected invasive staphylococcal infections. J Ped Infect Dis. 2013;2(3):259\u2013262."},{"issue":"6","key":"i1551-6776-24-4-296-b11","series-title":"Pediatrics","article-title":"The impact of pediatric-specific vancomycin dosing guidelines: a quality improvement initiative","volume":"139","year":"2017","unstructured":"Miloslavsky\n              M\n            , GallerMF, MoawadI, \n          et al. The impact of pediatric-specific vancomycin dosing guidelines: a quality improvement initiative. Pediatrics. 2017;139(6):e20162423. doi:10.1542\/peds.2016\u20132423."},{"issue":"10","key":"i1551-6776-24-4-296-b12","series-title":"Pediatr Infect Dis J","first-page":"1077","article-title":"Desired vancomycin trough serum concentration for treating invasive methicillin-resistant staphylococcal infections","volume":"32","year":"2013","unstructured":"Frymoyer\n              A\n            , GuglielmoBJ, HershAL.\n          Desired vancomycin trough serum concentration for treating invasive methicillin-resistant staphylococcal infections. Pediatr Infect Dis J. 2013;32(10):1077\u20131079."},{"issue":"12","key":"i1551-6776-24-4-296-b13","series-title":"Pharmacotherapy","first-page":"1278","article-title":"Vancomycin dosing in children and young adults: back to the drawing board","volume":"33","year":"2013","unstructured":"Camaione\n              L\n            , ElliottK, Mitchell-Van SteeleA, \n          et al. Vancomycin dosing in children and young adults: back to the drawing board. Pharmacotherapy. 2013;33(12):1278\u20131287."},{"issue":"6","key":"i1551-6776-24-4-296-b14","series-title":"J Pediatr Pharmacol Ther","first-page":"486","article-title":"Frequency of and risk factors for acute kidney injury associated with vancomycin use in the pediatric intensive care unit","volume":"21","year":"2016","unstructured":"Bonazza\n              S\n            , BreseeLC, KraftT, \n          et al. Frequency of and risk factors for acute kidney injury associated with vancomycin use in the pediatric intensive care unit. J Pediatr Pharmacol Ther. 2016;21(6):486\u2013493."},{"issue":"12","key":"i1551-6776-24-4-296-b15","series-title":"Ann Pharmacother","first-page":"1555","article-title":"Factors associated with acute kidney injury in children receiving vancomycin","volume":"48","year":"2014","unstructured":"Sinclair\n              EA\n            , YenokyanG, McMunnA, \n          et al. Factors associated with acute kidney injury in children receiving vancomycin. Ann Pharmacother. 2014;48(12):1555\u20131562."},{"issue":"2","key":"i1551-6776-24-4-296-b16","series-title":"J Pediatric Infect Dis Soc.","first-page":"127","article-title":"Are elevated vancomycin serum trough concentrations achieved within the first 7 days of therapy associated with acute kidney injury in children?","volume":"3","year":"2014","unstructured":"Knoderer\n              CA\n            , NicholsKR, LyonKC, \n          et al. Are elevated vancomycin serum trough concentrations achieved within the first 7 days of therapy associated with acute kidney injury in children?J Pediatric Infect Dis Soc.2014;3(2):127\u2013131."},{"issue":"17","key":"i1551-6776-24-4-296-b17","series-title":"N Engl J Med","first-page":"1098","article-title":"Simplified calculation of body-surface area","volume":"317","year":"1987","unstructured":"Mosteller\n              RD.\n            \n          \n          Simplified calculation of body-surface area. N Engl J Med. 1987;317(17):1098. doi:10.1056\/NEJM198710223171717."},{"issue":"3","key":"i1551-6776-24-4-296-b18","series-title":"Pediatr Clin North Am","first-page":"571","article-title":"The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents","volume":"34","year":"1987","unstructured":"Schwartz\n              GJ\n            , BrionLP, SpitzerA.\n          The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am. 1987;34(3):571\u2013590."},{"key":"i1551-6776-24-4-296-b19","unstructured":"Centers for Disease Control and Prevention. \n          Obesity and overweight: defining childhood obesity. https:\/\/www.cdc.gov\/obesity\/childhood\/defining.html. Accessed April 2, 2019.","article-title":"Obesity and overweight: defining childhood obesity"},{"issue":"3","key":"i1551-6776-24-4-296-b20","series-title":"J Pediatr","first-page":"422","article-title":"Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children","volume":"168","year":"2011","unstructured":"McKamy\n              S\n            , HernandezE, JahngM, \n          et al. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr. 2011;168(3):422\u2013426."},{"issue":"1","key":"i1551-6776-24-4-296-b21","series-title":"Am J Health Syst Pharm","first-page":"82","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus of the American Society of Health-Systems Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","year":"2009","unstructured":"Rybak\n              M\n            , LomaestroB, RotschaferJC, \n          et al. Therapeutic monitoring of vancomycin in adult patients: a consensus of the American Society of Health-Systems Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66(1):82\u201398."},{"issue":"23","key":"i1551-6776-24-4-296-b22","series-title":"Am J Health Syst Pharm","first-page":"2066","article-title":"Evaluation of a pediatric continuous-infusion vancomycin therapy guideline","volume":"69","year":"2012","unstructured":"McKamy\n              S\n            , ChenT, LeeM, \n          et al. Evaluation of a pediatric continuous-infusion vancomycin therapy guideline. Am J Health Syst Pharm. 2012;69(23):2066\u20132071."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/24\/4\/article-p296.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/24\/4\/296\/2468192\/1551-6776-24_4_296.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/24\/4\/article-p296.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/24\/4\/article-p296.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:43:24Z","timestamp":1747356204000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/24\/4\/article-p296.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":22,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-24.4.296","relation":{},"ISSN":["1551-6776"],"issn-type":[{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2019]]}}}